Category: imidazoles-derivatives

Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. 1739-84-0, formula is C5H8N2, Name is 1,2-Dimethyl-1H-imidazole. Their solubility in alcohol is lower than that in water and decreases with increasing molecular weight of the alcohols . HPLC of Formula: 1739-84-0.

Valverde, David;Porcar, Raul;Lozano, Pedro;Garcia-Verdugo, Eduardo;Luis, Santiago V. research published 《 Multifunctional Polymers Based on Ionic Liquid and Rose Bengal Fragments for the Conversion of CO₂ to Carbonates》, the research content is summarized as follows. Supported ionic liquid-like phases (SILLPs) containing Rose Bengal (RB) units are used to develop organocatalytic systems for the cycloaddition of CO₂ to epoxides. The activity of the supported RB fragments can be fine-tuned by controlling the nature of the SILLPs (i.e., substitution at the imidazolium ring, crosslinking degree of the polymeric matrix, loading, etc.). Such a catalytic system prepared from cheap, simple, and com. available components provides high activity and stability, with no decay in activity for at least 10 days of continuous use under flow conditions. SILLPs containing imidazolium and Rose Bengal units are used to enhancing organocatalytic systems and provide high activity and stability under batch and flow conditions.

1739-84-0, 1,2-Dimethylimidazole is used in the synthesis of 1,2-dimethyl-3-n-butylimidazoliumchloride and 1,2-dimethyl-3-n-propylimidazolium chloride. It also can be used in the synthesis of 1-(2-methoxyethyl)-2,3-dimethylimidazolium chloride and hexafluorophosphate salts.
1,2-Dimethylimidazole is a heterocyclic compound that contains nitrogen and carbon. It can be produced by the reaction between glyoxal and fatty acid in the presence of a base. 1,2-Dimethylimidazole has been shown to have biological properties such as an antioxidant effect. It is also used as a chemical intermediate for production of other chemicals such as 2-methylimidazole and 3-methylimidazole. 1,2-Dimethylimidazole has been shown to react with metal carbonyls to produce methylimines, which are useful intermediates in organic synthesis. The reaction mechanism involves hydrogen bonding and steric interactions between the imidazole ring and the metal carbonyl reactant., HPLC of Formula: 1739-84-0

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. 10111-08-7, formula is C4H4N2O, Name is 1H-Imidazole-2-carbaldehyde. Their solubility in alcohol is lower than that in water and decreases with increasing molecular weight of the alcohols . Reference of 10111-08-7.

van Essen, Machiel;Thur, Raymond;van den Akker, Luuk;Houben, Menno;Vankelecom, Ivo F. J.;Nijmeijer, Kitty;Borneman, Zandrie research published 《 Tailoring the separation performance of ZIF-based mixed matrix membranes by MOF-matrix interfacial compatibilization》, the research content is summarized as follows. Controlling the metal-organic framework (MOF)-matrix interface is a useful strategy to improve the gas separation performance of mixed matrix membranes (MMMs). Although polymer blending has been investigated to enhance MMM performances, its true strength, i.e., aligning polymer and additive chemistries to improve interfacial compatibility and ultimately the separation performance, is only poorly investigated. In this work we demonstrate how controlling interfacial chemistries by polymer blending is an effective tool to tune the membrane performance. Three isoreticular zeolitic imidazolate frameworks (ZIFs) and two matrix polymers (Matrimid and polybenzimidazole oPBI (PBI)) were used to prepare the MMMs. The ZIF linker functionality strongly determined the extent of the effect of PBI addition in the MMMs. For both the hydrophobic ZIF-7 and ZIF-8-based MMMs, PBI compatibilized the MOF-matrix interface and increased the CO₂/N₂ separation factor while slightly decreasing the permeability. Contrarily, the separation performance of the hydrophilic ZIF-90 MMM was not affected by PBI incorporation. Addnl., the MMM permeability followed the trend of the ZIF pore geometries and linker flexibilities. These results proved that MOF-matrix interfacial compatibility can effectively be controlled by polymer blending and that the extent of control is determined by a subtle balance between the MOF linker functionality and matrix chem.

Reference of 10111-08-7, 1H-Imidazole-2-carbaldehyde, also known as 1H-Imidazole-2-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
1H-Imidazole-2-carboxaldehyde is a novel PTP1b inhibitor with potential application to treat type 2 diabetes.
1H-Imidazole-2-carboxaldehyde is a broad-spectrum antimicrobial that has been shown to inhibit the growth of bacteria by interfering with protein synthesis. It binds to the cytosolic protein and receptor molecule, which are involved in the activation of bacterial enzymes. Imidazole-2-carboxaldehyde reacts with anhydrous sodium and copper complex to produce hydrogen bonds, which prevent the formation of the nitrogen atoms necessary for cellular processes. This chemical also has biological properties such as glyoxal, which inhibits bacterial growth by reacting with amino groups on proteins., 10111-08-7.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . 1739-84-0, formula is C5H8N2, Name is 1,2-Dimethyl-1H-imidazole. In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with an increase of the alkyl chain length of the alcohols. Recommanded Product: 1,2-Dimethyl-1H-imidazole.

Vedovello, Priscila;de Oliveira Gomes, Ana Catarina;da Rocha Oliveira, Lucas Mendonca;Cruz, Sandra Andrea;Paranhos, Caio Marcio research published 《 Short alkyl chain length ionic liquid as organic modifier in polypropylene/clay nanocomposite: a thermal comparative study》, the research content is summarized as follows. The most common polymeric nanocomposites are constituted of organically-modified clays. Generally, these organic modifiers are based on quaternary ammonium salts. These systems have as disadvantage the low thermal resistance of its modifiers under processing. Ionic liquids (IL) with different mol. structures can be used as organic modifier in lamellar clays-based polymeric nanocomposites, being promising not only to increase interactions between the nanoclay and the matrix, but also to increase the thermal resistance. In this study, polypropylene-based/montmorillonite nanocomposites were compared from two different organic modifiers. The use of short alkyl chain length imidazolium-based IL as montmorillonite modifier was investigated in terms of the thermal stability when compared to the usual quaternary ammonium salt surfactant. Integral procedure decomposition temperature was employed to determine the effect of these two different organoclay modifiers in PP-nanocomposites. The activation energy for these samples was calculated using Flynn-Wall-Ozawa (FWO) method. It was also used the multiple linear regression anal. to calculate the activation energy in order to evaluate the accuracy of this method when applied to nanocomposites.

Recommanded Product: 1,2-Dimethyl-1H-imidazole, 1,2-Dimethylimidazole is used in the synthesis of 1,2-dimethyl-3-n-butylimidazoliumchloride and 1,2-dimethyl-3-n-propylimidazolium chloride. It also can be used in the synthesis of 1-(2-methoxyethyl)-2,3-dimethylimidazolium chloride and hexafluorophosphate salts.
1,2-Dimethylimidazole is a heterocyclic compound that contains nitrogen and carbon. It can be produced by the reaction between glyoxal and fatty acid in the presence of a base. 1,2-Dimethylimidazole has been shown to have biological properties such as an antioxidant effect. It is also used as a chemical intermediate for production of other chemicals such as 2-methylimidazole and 3-methylimidazole. 1,2-Dimethylimidazole has been shown to react with metal carbonyls to produce methylimines, which are useful intermediates in organic synthesis. The reaction mechanism involves hydrogen bonding and steric interactions between the imidazole ring and the metal carbonyl reactant., 1739-84-0.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 10111-08-7, formula is C4H4N2O, Name is 1H-Imidazole-2-carbaldehyde. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Recommanded Product: 1H-Imidazole-2-carbaldehyde.

Velasquez-Hernandez, Miriam de J.;Astria, Efwita;Winkler, Sarah;Liang, Weibin;Wiltsche, Helmar;Poddar, Arpita;Shukla, Ravi;Prestwich, Glenn;Paderi, John;Salcedo-Abraira, Pablo;Amenitsch, Heinz;Horcajada, Patricia;Doonan, Christian J.;Falcaro, Paolo research published 《 Modulation of metal-azolate frameworks for the tunable release of encapsulated glycosaminoglycans》, the research content is summarized as follows. Glycosaminoglycans (GAGs) are biomacromols. necessary for the regulation of different biol. functions. In medicine, GAGs are important com. therapeutics widely used for the treatment of thrombosis, inflammation, osteoarthritis and wound healing. However, protocols for the encapsulation of GAGs in MOFs carriers are not yet available. Here, we successfully encapsulated GAG-based clin. drugs (heparin, hyaluronic acid, chondroitin sulfate, dermatan sulfate) and two new biotherapeutics in preclin. stage (GM-1111 and HepSYL proteoglycan) in three different pH-responsive metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resultant GAG@MOF biocomposites present significant differences in terms of crystallinity, particle size, and spatial distribution of the cargo, which influences the drug-release kinetics upon applying an acidic stimulus. For a selected system, heparin@MOF, the released therapeutic retained its antithrombotic activity while the MOF shell effectively protects the drug from heparin lyase. By using different MOF shells, the present approach enables the preparation of GAG-based biocomposites with tunable properties such as encapsulation efficiency, protection and release.

10111-08-7, 1H-Imidazole-2-carbaldehyde, also known as 1H-Imidazole-2-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
1H-Imidazole-2-carboxaldehyde is a novel PTP1b inhibitor with potential application to treat type 2 diabetes.
1H-Imidazole-2-carboxaldehyde is a broad-spectrum antimicrobial that has been shown to inhibit the growth of bacteria by interfering with protein synthesis. It binds to the cytosolic protein and receptor molecule, which are involved in the activation of bacterial enzymes. Imidazole-2-carboxaldehyde reacts with anhydrous sodium and copper complex to produce hydrogen bonds, which prevent the formation of the nitrogen atoms necessary for cellular processes. This chemical also has biological properties such as glyoxal, which inhibits bacterial growth by reacting with amino groups on proteins., Recommanded Product: 1H-Imidazole-2-carbaldehyde

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole based anticancer drug find applications in cancer chemotherapy. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC). Electric Literature of 60-56-0.

Verma, Kanika;Lahariya, Ayush K.;Dubey, Shivangee;Verma, Anil K.;Das, Aparup;Schneider, Kristan A.;Bharti, Praveen K. research published 《 An integrated virtual screening and drug repurposing strategy for the discovery of new antimalarial drugs against Plasmodium falciparum phosphatidylinositol 3-kinase》, the research content is summarized as follows. The emergence and spread of drug resistance in Plasmodium falciparum, the parasite causing the most severe form of human malaria, is a major threat to malaria control and elimination programs around the globe. With P. falciparum having evolved widespread resistance against a number of previously widely used drugs, currently, artemisinin (ART) and its derivatives are the cornerstones of first-line treatments of uncomplicated malaria. However, growing incidences of ART failure reflect the spread of ART-resistant P. falciparum strains. Despite current efforts to understand the primary cause of ART resistance due to mutations in the Kelch 13 gene (PfK13), the mechanism underlying ART resistance is still not completely unclear and no feasible strategies to counteract the causes and thereby restoring the efficiency of ART have been developed. We use a polypharmacol. approach to identify potential drugs that can be used for the novel purpose (target). Of note, we have designed a multimodal stratagem to identify approved drugs with a potential antimalarial activity using computational drug reprofiling. Our investigations suggest that oxetacaine, simvastatin, repaglinide, aclidinium, propafenone, and lovastatin could be repurposed for malaria control and prevention.

60-56-0, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., Electric Literature of 60-56-0

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole is a five-membered heterocyclic moiety that possesses three carbon, two nitrogen, four hydrogen atoms, and two double bonds. 250285-32-6, formula is C27H37ClN2, Name is 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride. It is also known as 1, 3-diazole. It contains two nitrogen atoms, in which one nitrogen bear a hydrogen atom, and the other is called pyrrole type nitrogen. SDS of cas: 250285-32-6.

Vermersch, Francois;Yazdani, Sima;Junor, Glen P.;Grotjahn, Douglas B.;Jazzar, Rodolphe;Bertrand, Guy research published 《 Stable Singlet Carbenes as Organic Superbases》, the research content is summarized as follows. A simple exptl. procedure for scaling carbene Bronsted basicity was described. The results highlighted the strong basicity of pyrazol-4-ylidenes, a type of mesoionic carbene, also named cyclic-bentallenes (CBA). They were more basic (pK_aH >42.7 in acetonitrile) than the popular proazaphosphatrane Verkade bases and even the Schwesinger phosphazene superbase P₄(^tBu). The basicity of these compounds can readily be tuned, and they are accessible in multigram quantities. These results open new avenues for carbon centered superbases.

SDS of cas: 250285-32-6, 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, also known as 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, is a useful research compound. Its molecular formula is C27H37ClN2 and its molecular weight is 425 g/mol. The purity is usually 95%.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride has been used to generate N-heterocyclic carbene catalysts for use in carbonylative cross-coupling of pyridyl halides with aryl boronic acids.

1,3-Bis(2,6-diisopropylphenyl)imidazolium Chloride is an imidazolium salt that is active against all stages of Trypanosoma cruzi and may represent a promising candidate for treatment of Chagas disease.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is an organic compound that is used as a solvent. It was originally synthesized by reacting triethyl orthoformate with 2,6-diisopropylaniline. This reaction formed the corresponding imidazolium salt. The synthesis of this compound was later improved by using ring-opening polymerization of glycolide and furfural. 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is mainly used to extract estradiol from urine samples in clinical laboratories., 250285-32-6.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole based anticancer drug find applications in cancer chemotherapy. 1739-84-0, formula is C5H8N2, Name is 1,2-Dimethyl-1H-imidazole. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC). Computed Properties of 1739-84-0.

Vieira, Michele O.;Monteiro, Wesley F.;Ferreira, Thuany M.;Domingos, Josiel B.;Dupont, Jairton;dos Santos, Francisco P.;Scholten, Jackson D. research published 《 Surface active SNS-based dicationic ionic liquids containing amphiphilic anions: Experimental and theoretical studies of their structures and organization in solution》, the research content is summarized as follows. Surface active ionic liquids (SAILs) have been reported as new media that collectively offer the advantages of the aqueous and oily phases. In particular, dicationic ionic liquids (DILs) have attracted much interests because their tunable physicochem. properties allow them to act as sustainable active catalysts in chem. reactions (CO₂ conversion, esterification) and also as extraction media to remove drugs/pollutants from aqueous systems. In order to better understand this class of ILs, this work describes new strategies for the synthesis of SNS-based dicationic ILs containing amphiphilic anions ([C₁₂SO₄]^–, [C₁₂ESO₄]^–, [C₁₂BSO₃]^–and [C₁₂SAR]^–) and the evaluation of their structural organization and aggregation level in solution The results obtained by exptl. techniques (FTIR, TGA, DSC, POM, ESI-MS, DLS and NMR) combined with those achieved by theor. DFT calculations revealed that the anion has an important function to modulate the properties of the SNS-based ILs in solution, while the presence of a Me group at the C2 position of the imidazolium ring seems to be not sufficient to change such physicochem. properties. The ILs containing the anion [CC₁₂BSO₃]^– showed a superior ionic organization in solution due to the cationic aggregates observed in the ESI(+) mode and the large size of aggregates observed by DLS. This behavior may be assigned to a close proximity of the cationic imidazolium ring and the aromatic ring in the anion (π-π interaction), and by NMR anal. (ROESY and DOSY) it was possible to confirm interactions between cation and anion. Therefore, the theor. and exptl. results obtained for the SNS-based dicationic ILs containing amphiphilic anions indicate that these ILs can be applied as media in both pure and/or solution systems for many sustainable applications.

Computed Properties of 1739-84-0, 1,2-Dimethylimidazole is used in the synthesis of 1,2-dimethyl-3-n-butylimidazoliumchloride and 1,2-dimethyl-3-n-propylimidazolium chloride. It also can be used in the synthesis of 1-(2-methoxyethyl)-2,3-dimethylimidazolium chloride and hexafluorophosphate salts.
1,2-Dimethylimidazole is a heterocyclic compound that contains nitrogen and carbon. It can be produced by the reaction between glyoxal and fatty acid in the presence of a base. 1,2-Dimethylimidazole has been shown to have biological properties such as an antioxidant effect. It is also used as a chemical intermediate for production of other chemicals such as 2-methylimidazole and 3-methylimidazole. 1,2-Dimethylimidazole has been shown to react with metal carbonyls to produce methylimines, which are useful intermediates in organic synthesis. The reaction mechanism involves hydrogen bonding and steric interactions between the imidazole ring and the metal carbonyl reactant., 1739-84-0.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents. Electric Literature of 60-56-0.

von Itzstein, Mitchell S.;Gonugunta, Amrit S.;Wang, Yiqing;Sheffield, Thomas;Lu, Rong;Ali, Sadia;Fattah, Farjana J.;Xie, Donglu;Cai, Jennifer;Xie, Yang;Gerber, David E. research published 《 Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors》, the research content is summarized as follows. Thyroid dysfunction is among the most common autoimmune diseases and immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAE). We determined the association between longitudinal thyroid function and clin. outcomes in patients treated with ICI. We identified all patients treated with ICI at UT Southwestern Medical Center from Jan. 1, 2011, through Dec. 31, 2020. We defined normal TSH (TSH) and free thyroxine (FT4) levels according to institutional reference range. We defined clin. thyroid dysfunction using established criteria incorporating labs and treatment. We determined the association between thyroid function and overall survival (OS) using Kaplan-Meier curves, log-rank tests, and multivariate Cox proportional hazards model. A total of 1781 patients were included in analyses, of whom 381 (21%) had abnormal baseline TSH. Patients with abnormal baseline TSH were more likely to be female, have kidney cancer, and initiate levothyroxine after ICI initiation (all P < 0.001). Patients with abnormal baseline TSH had inferior OS (median 16 vs 27 mo; P < 0.001). Among patients with normal baseline TSH, those who had abnormal TSH after ICI initiation had improved OS (median 41 vs 22 mo; P < 0.001). In a multivariate Cox model, abnormal baseline TSH was associated with worse OS (HR 1.62; 95% CI, 1.30-2.02; P < 0.001), while initiation of levothyroxine after ICI initiation was associated with improved OS (HR 0.62; 95% CI, 0.44-0.88; P = 0.008). ICI-induced thyroid dysfunction is associated with improved survival, although abnormal TSH prior to ICI initiation is associated with inferior survival. Precis: Thyroid abnormalities occur commonly in the general population and as immunotherapy toxicities. We found that immunotherapy-induced thyroid dysfunction is associated with better survival, but pre-existing thyroid abnormalities convey worse outcomes.

60-56-0, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., Electric Literature of 60-56-0

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Category: imidazoles-derivatives.

Vuijk, Floris A.;de Bruin, Christiaan;Peeters-Scholte, Cacha M. P. C. D.;Notting, Irene C. research published 《 Recurrent Intracranial Hypertension in a Toddler with Graves’ Disease》, the research content is summarized as follows. Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure without an evident cause. Obesity and the female sex have been recognized as risk factors for the development of this syndrome. Until now, Graves disease has only been described in the literature as the probable cause of IIH in 7 patients. This report describes the case of a young girl with Graves disease presenting with symptoms of intracranial hypertension (IH). A 21-mo-old girl presented with progressive symptoms of poor weight gain and bilateral exophthalmos. She also experienced difficulty sleeping, diarrhea multiple times per day, irritability, and heat intolerance. Laboratory investigation showed elevated free T4, fully suppressed TSH, and elevated anti-TSH antibodies, consistent with a diagnosis of new-onset Graves disease. She was successfully treated with monotherapy thiamazole, titrated to the lowest possible dose of 1.25 mg once daily with normalization of thyroid function tests within 3 mo of treatment initiation. After 18 mo of treatment, her condition unexpectedly deteriorated as papilledema and slight esotropia were found at a routine checkup. An MRI and lumbar puncture showed increased intracranial pressure, but no underlying anatomical cause for the IH was found. Acetazolamide therapy was started, and papilledema in both eyes resolved within weeks. Unfortunately, papilledema has recurred several times over the following 2 years when attempts were made to decrease the acetazolamide dose. This case report is the first to describe a very young patient who developed significant IIH in the chronic stage of Graves disease. IIH development seemed to be related to the progression of the Graves ophthalmopathy, rather than initiation of thiamazole therapy or fluctuations in serum fT4 levels.

Category: imidazoles-derivatives, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., 60-56-0.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 250285-32-6, formula is C27H37ClN2, Name is 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Quality Control of 250285-32-6.

Wang, Fei;Su, Yanning;Li, Yuanzhen;Wei, Dongyuan;Sun, Hanxue;Zhu, Zhaoqi;Liang, Weidong;Li, An research published 《 Salt-Resistant Photothermal Materials Based on Monolithic Porous Ionic Polymers for Efficient Solar Steam Generation》, the research content is summarized as follows. The exploitation of salt-resistant photothermal materials is of great importance for practical solar desalination. Herein, we report, for the first time, the synthesis of monolithic porous ionic polymers (PIPs) coated with polypyrrole (PPy) as self-desalting photothermal materials for efficient solar steam generation. Based on their good thermal insulation, the desired mesopores, and the extremely high light absorption (98%), the PPy-coated PIPs exhibit a high evaporation efficiency of 89% under 1 sun irradiation and superior durability in terms of evaporation efficiency in high-salinity (30 wt %) brine. Quite different from the existing salt-resistant photothermal materials by the artificial creation of aligned channels or Janus wettability, interestingly, the self-desalting of our materials depends on their intrinsically porous ionic framework, which could serve as “ions barrier” to shield the cations of saline solution These findings may provide an opportunity for future design and fabrication of self-desalting photothermal materials by only one-pot synthesis without a further complicated process.

Quality Control of 250285-32-6, 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, also known as 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, is a useful research compound. Its molecular formula is C27H37ClN2 and its molecular weight is 425 g/mol. The purity is usually 95%.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride has been used to generate N-heterocyclic carbene catalysts for use in carbonylative cross-coupling of pyridyl halides with aryl boronic acids.

1,3-Bis(2,6-diisopropylphenyl)imidazolium Chloride is an imidazolium salt that is active against all stages of Trypanosoma cruzi and may represent a promising candidate for treatment of Chagas disease.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is an organic compound that is used as a solvent. It was originally synthesized by reacting triethyl orthoformate with 2,6-diisopropylaniline. This reaction formed the corresponding imidazolium salt. The synthesis of this compound was later improved by using ring-opening polymerization of glycolide and furfural. 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is mainly used to extract estradiol from urine samples in clinical laboratories., 250285-32-6.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem